Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
MWN-AI** Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to enhance the immune response against cancer and other immune-mediated conditions, announced its financial results for Q4 and the full year 2025, alongside a strategic business update. CEO Daniel J. Hicklin, Ph.D., highlighted the initiation of a process to explore various strategic alternatives aimed at maximizing shareholder value, which could include a potential sale of the company, merger, or collaborative partnerships. To aid in this evaluation, Werewolf has engaged Piper Sandler & Co. as its financial advisor.
As of December 31, 2025, the company's cash and cash equivalents stood at $57.1 million, down from $65.7 million at the end of Q3 2025, which the company believes will sustain its operations until late 2026. The company reported a significant reduction in research and development expenses to $6.9 million for Q4 2025, compared to $15.7 million in Q4 2024, resulting in a total of $44.8 million for the full year. General and administrative expenses also declined, showing efficiencies in operational costs.
Despite ongoing operational losses, Werewolf reported a net loss of $8.4 million for Q4 2025, down from $20.4 million in the prior year, and a total net loss of $60.8 million for the year compared to $70.5 million in 2024. The company continues to advance its proprietary INDUKINE and INDUCER platforms, which are designed to selectively activate immune responses in the tumor microenvironment, with several clinical-stage candidates in development. However, the company cautioned investors regarding the inherent uncertainties involved in strategic evaluations and clinical developments.
MWN-AI** Analysis
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) recently announced its fourth quarter and full year 2025 financial results, revealing both challenges and opportunities for investors. While the company demonstrated a reduction in net losses and operational expenses compared to 2024, its cash reserves fell significantly from $110.99 million to $57.05 million, signaling a need for caution.
The strategic evaluation process initiated by management, under the guidance of Piper Sandler & Co., is a pivotal moment for the company. The exploration of potential avenues to maximize shareholder value, including mergers or asset sales, could lead to transformative agreements. However, the lack of a defined timeline raises uncertainty regarding the outcome, making it essential for investors to closely monitor developments as they unfold.
With cash expected to last until Q4 2026, Werewolf's funding is somewhat secure in the short term, but the significant drop in cash reserves requires scrutiny. Investors should assess the implications of this reduced liquidity on the company’s operational strategy and R&D capabilities. The reduction in R&D expenses to $44.8 million for the full year suggests a pivot towards cost management, but this could also imply constraints on advancing clinical candidates like WTX-124 and WTX-330.
In terms of clinical candidates, Werewolf’s innovative INDUKINE and INDUCER platforms continue to represent a potential upside. However, the lack of collaboration revenue in 2025 indicates that partnerships are yet to materialize, further emphasizing the need for concrete strategic actions.
In sum, while Werewolf Therapeutics holds potential for long-term gains through its promising technologies, the current strategic uncertainty and decreased cash flow merit caution. Investors should remain vigilant for upcoming announcements that could clarify the company’s path forward and impact stockholder value significantly.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2025.
“We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “Such measures may include, among other options, a sale of the Company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. In addition to our clinical-stage candidates and our named earlier-stage candidates, our INDUKINE and INDUCER platforms provide exciting opportunities to apply our differentiated masking and protease linker technology in multiple additional modalities.”
The Company has engaged Piper Sandler & Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process. The Company does not have a defined timeline for the exploration and evaluation of strategic alternatives and cannot confirm that the process will result in any strategic alternative being announced or consummated. The Company cannot provide any commitment regarding when or if this strategic evaluation process will result in any type of transaction, and there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value. The Company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or the Company has otherwise determined that further disclosure is appropriate.
Financial Results for the Fourth Quarter and Full Year 2025:
- Cash position: As of December 31, 2025, cash and cash equivalents were $57.1 million, compared to $65.7 million as of September 30, 2025. The Company believes its cash and cash equivalents as of December 31, 2025, will be sufficient to fund operational expenses and capital requirements into the fourth quarter of 2026.
- Research and development expenses: Research and development expenses were $6.9 million for the fourth quarter of 2025, compared to $15.7 million for the same period in 2024. Research and development expenses were $44.8 million for the full year 2025, compared to $56.4 million for the full year 2024.
- General and administrative expenses: General and administrative expenses were $2.5 million for the fourth quarter of 2025, compared to $4.6 million for the same period in 2024. General and administrative expenses were $15.8 million for the full year 2025, compared to $19.0 million for the full year 2024.
- Net loss: Net loss was $8.4 million for the fourth quarter of 2025, compared to $20.4 million for the same period in 2024. Net loss was $60.8 million for the full year 2025, compared to $70.5 million for the full year 2024.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer, and its second INDUCER candidate, WTX-2022, targets CDH6 for ovarian and kidney cancer. To learn more visit www.werewolftx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management, including potential strategic partnerships; Werewolf’s exploration and evaluation of strategic alternatives and the ability of any such strategic alternative to provide stockholder value; the projection of the cash runway; the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; the Company’s ability to manage cash resources and obtain additional cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the Company’s ability to continue as a going concern; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
| Werewolf Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited) (amounts in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Collaboration revenue | $ | — | $ | — | $ | — | $ | 1,885 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 6,933 | 15,727 | 44,830 | 56,434 | |||||||||||
| General and administrative | 2,485 | 4,621 | 15,847 | 19,045 | |||||||||||
| Total operating expenses | 9,418 | 20,348 | 60,677 | 75,479 | |||||||||||
| Operating loss | (9,418 | ) | (20,348 | ) | (60,677 | ) | (73,594 | ) | |||||||
| Other income (expense) | 1,037 | (52 | ) | (145 | ) | 3,079 | |||||||||
| Net loss | $ | (8,381 | ) | $ | (20,400 | ) | $ | (60,822 | ) | $ | (70,515 | ) | |||
| Net loss per common share, basic | $ | (0.17 | ) | $ | (0.46 | ) | $ | (1.32 | ) | $ | (1.63 | ) | |||
| Net loss per common share, diluted | $ | (0.20 | ) | $ | (0.46 | ) | $ | (1.33 | ) | $ | (1.63 | ) | |||
| Weighted-average common shares outstanding, basic | 48,425,423 | 44,478,140 | 46,018,888 | 43,332,088 | |||||||||||
| Weighted-average common shares outstanding, diluted | 49,216,787 | 44,478,140 | 46,810,252 | 43,859,664 |
| Werewolf Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited) (amounts in thousands) | |||||
| December 31, 2025 | December 31, 2024 | ||||
| Cash and cash equivalents | $ | 57,050 | $ | 110,995 | |
| Working capital | $ | 22,438 | $ | 97,886 | |
| Total assets | $ | 69,396 | $ | 126,929 | |
| Total notes payable, net of discount and issuance costs | $ | 28,236 | $ | 26,095 | |
| Total stockholders’ equity | $ | 24,805 | $ | 73,390 | |
Company Contact:
Steven Bloom
Chief Business Officer
Werewolf Therapeutics
sbloom@werewolftx.com
Piper Sandler Contacts:
Peter Day
Managing Director,
Piper Sandler & Co.
peter.day@psc.com
Michael Burton-Williams
Executive Director,
Piper Sandler & Co.
michael.burton-williams@psc.com
FAQ**
Given Werewolf Therapeutics Inc. (Nasdaq: HOWL) is exploring strategic alternatives, what specific metrics or indicators does the company consider critical for maximizing stockholder value during this evaluation process?
How does Werewolf Therapeutics Inc. (Nasdaq: HOWL) plan to allocate its remaining cash reserves of $57.1 million to ensure continued operation and development through the fourth quarter of 2026?
What are the expected timelines for the clinical development and potential regulatory approval of Werewolf Therapeutics Inc. (Nasdaq: HOWL) leading candidates such as WTX-124 and WTX-330?
Can Werewolf Therapeutics Inc. (Nasdaq: HOWL) provide insights into how its INDUKINE and INDUCER platforms differentiate from conventional therapies and their potential for future partnerships or licensing agreements?
**MWN-AI FAQ is based on asking OpenAI questions about Werewolf Therapeutics Inc. (NASDAQ: HOWL).
NASDAQ: HOWL
HOWL Trading
-9.93% G/L:
$0.3963 Last:
299,845 Volume:
$0.454 Open:
